STOCK TITAN

aTyr Pharma to Participate in Piper Sandler Investor Lung Day

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

On October 11, 2021, aTyr Pharma (Nasdaq: LIFE) announced that its CEO, Sanjay S. Shukla, will participate in a fireside chat during the Piper Sandler Virtual Investor Day on October 15, 2021, at 9:00 AM ET. The event focuses on developing therapeutics for lung indications and will be moderated by Ted Tenthoff, a Senior Research Analyst at Piper Sandler. A replay of the discussion will be available on aTyr's investor website for 90 days following the event. aTyr Pharma specializes in innovative medicines based on tRNA synthetases for inflammatory lung diseases.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler Virtual Investor Day: Developing Therapeutics for Lung Indications on Friday, October 15, 2021, at 9:00am ET / 6:00am PT.

The discussion will be moderated by Ted Tenthoff, Senior Research Analyst at Piper Sandler.

Following the event, a replay of the fireside chat will be available on the Investor’s section of the company’s website at www.atyrpharma.com and will be available for at least 90 days.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com


FAQ

What date is aTyr Pharma's fireside chat scheduled for?

The fireside chat is scheduled for October 15, 2021.

Who is participating in the Piper Sandler Virtual Investor Day for aTyr Pharma?

Sanjay S. Shukla, the CEO of aTyr Pharma, will participate.

What will aTyr Pharma discuss during the investor day event?

The discussion will focus on developing therapeutics for lung indications.

How can I access the replay of aTyr Pharma's fireside chat?

The replay will be available on aTyr's investor website for at least 90 days.

What is the ticker symbol for aTyr Pharma?

The ticker symbol for aTyr Pharma is LIFE.

aTyr Pharma, Inc.

NASDAQ:LIFE

LIFE Rankings

LIFE Latest News

LIFE Stock Data

131.12M
69.01M
2.62%
61.69%
0.5%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO